Brokerages predict that Magenta Therapeutics Inc (NASDAQ:MGTA) will report earnings per share (EPS) of ($0.55) for the current quarter, according to Zacks. Zero analysts have issued estimates for Magenta Therapeutics’ earnings. The lowest EPS estimate is ($0.55) and the highest is ($0.54). The company is scheduled to announce its next quarterly earnings report on Thursday, February 14th.
According to Zacks, analysts expect that Magenta Therapeutics will report full-year earnings of ($3.19) per share for the current fiscal year, with EPS estimates ranging from ($3.23) to ($3.15). For the next year, analysts expect that the company will post earnings of ($2.05) per share, with EPS estimates ranging from ($2.67) to ($1.12). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Magenta Therapeutics.
Magenta Therapeutics (NASDAQ:MGTA) last issued its earnings results on Thursday, November 8th. The company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.18.
Shares of NASDAQ MGTA opened at $6.12 on Friday. Magenta Therapeutics has a 12 month low of $5.31 and a 12 month high of $16.33.
A number of large investors have recently added to or reduced their stakes in MGTA. Point72 Hong Kong Ltd acquired a new stake in Magenta Therapeutics during the 2nd quarter valued at approximately $109,000. Point72 Asset Management L.P. acquired a new stake in Magenta Therapeutics during the 2nd quarter valued at approximately $109,000. Northern Trust Corp acquired a new stake in Magenta Therapeutics during the 2nd quarter valued at approximately $179,000. Bollard Group LLC acquired a new stake in Magenta Therapeutics during the 3rd quarter valued at approximately $360,000. Finally, Platinum Investment Management Ltd. acquired a new stake in Magenta Therapeutics during the 2nd quarter valued at approximately $675,000. 30.79% of the stock is owned by institutional investors and hedge funds.
About Magenta Therapeutics
Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.
Recommended Story: What impact do institutional investors have on markets?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.